I intend to collate answers to this message and to forward them...

I intend to collate answers to this message and to forward them to Noxopharm. I want to know your views on things that Noxopharm might do better.


The market cap of Noxopharm is relatively low for a company with their range of assets, and while some of the drop in recent months can be attributed to a Fund that was apparently forced to get out of biotech, Noxopharm has clearly been unable to convince the Market of the value of its assets.

The License deal with HIMR is one example. HIMR technology looks like it will improve efficacy of every mRNA vaccine (including flu shots) by reducing side effects, which will enable doses to be increased. The Market has not realized that there should be a stampede for this technology, or that there could be a bidding war between manufacturers, or that this program alone could be a company-maker.

What would you do to improve matters?